Skip to main content
. 2013 Sep 1;13(11):1–76.

Table 17: Impact of eTools on HbA1c Tests Conducted.

Author, Year Study Design Length of Follow-up Sample Size, n (Intervention/Control) Results (Intervention/Control) Effect Estimate (95% CI)
Montori et al, 2002 (37) RCT 24 months 399/208 99%/94% of patients aORa4.5 (1.0–19.5)
Branger et al, 1999 (32) Observational 1 year 215/60 177 (0.8)/9 (0.2) measures (per patient) Mean differenceb 0.60 (0.21−0.99)
Cebul et al, 2011 (38) Observational 1 year 24,547/2,660 94.6%/85.6% of patients aDiffb 7.2 (0.4–14.0)
Henderson et al, 2010 (36) Observational 16 months 3,432/688 encounters 25.1/17.6 per 100 encounters aRCc 3.10 (NR) P = 0.24
Herrin et al, 2012 (40) Observational 5 years 10,017/35,033 patient years 97.6%/92.7% of patients aORd 0.6 (0.5−0.6)
Wells et al, 1996 (42) Observational 23 months 2,049/1,190 93%/73% of patients OR 4.89 (3.95–6.04)

Abbreviations: aDiff, adjusted risk difference; aOR, adjusted odds ratio; aRC, adjusted regression correlation; CI, confidence interval; eTool, electronic tool; FRACGP, Fellowship of the Royal Australian College of General Practitioners; GP, general practitioner; HbA1c, hemoglobin A1c; NR, not reported; OR, odds ratio; RCT, randomized controlled trial.

a

Adjusted with logistic regression, further details not provided.

b

Adjusted for insurance type, age, sex, race/ethnic group, language preference, estimated household income, and education level.

c

Adjusted for GP age, GP sex, FRACGP status, work in deputizing services in preceding month, bulk billing for all patients, practice accreditation status, presence of a practice nurse.

d

Adjusted for age, sex, insulin usage, and year of study.